Navigate Fool.com
Will OREX beat
the market?
Community Rating: 2 Stars: Unattractive

5.70 0.36 (6.74%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.38
Previous Close $5.34
Daily Range $5.38 - $5.79
52-Week Range $4.60 - $7.84
Market Cap $635.8M
P/E Ratio -6.68
Dividend (Yield) $0.00 (0.0%)
Volume 2,156,549
Average Daily Volume 2,479,075
Current FY EPS -$0.07

How do you think OREX
will perform against the market?

Top OREX Bull/Bear Pitches


zzlangerhans (< 20)
Submitted September 23, 2011

Let me see if I have this straight. Orexigen is worth 3 bucks a share when they don't have a shot at Contrave approval until after they complete a five year cardiovascular outcomes study that will co … More

1 Replies Reply Report this Post

pastordisaster (4.23)
Submitted July 29, 2011

This wonderful company has just repriced a good portion of their outstanding employee stock options to current price levels.<br /><br />The CEO just repriced ALL of his 2,260,800 options that ranged i … More

1 Replies Reply Report this Post

News & Commentary

Biotech Tweet of the Week: Love Being Private

Investors often ignore private biotechs because they can't buy shares, but investors in companies such as InterMune and the obesity drug makers -- Arena Pharmaceuticals, VIVUS, and Orexigen -- need to follow their privately-held competitors.

Why GlaxoSmithKline PLC Shrugged Off Alli's Recall

GlaxoSmithKline issued a voluntary recall for its OTC weight-loss pill Alli last week. Will this recall have a material impact on GlaxoSmithKline's business?

Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?

Many of the world's leading causes of death are quite obvious, but this global killer could be lurking in your refrigerator right now!

Biotech Tweets of the Week: Gilead Sciences and Orexigen

Two tweets highlight expectations of Gilead Sciences and Orexigen.

Could Orexigen Therapeutics Be Another Arena or VIVUS?

Orexigen Therapeutics has yet to follow in the footsteps of its competitors prior to approval of their obesity medications. Why?

Orexigen Therapeutics Reduces Q4 Loss by 34%

Lower research and development expenses help lower Orexigen's quarterly loss.

Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?

A number of factors are holding back obesity therapies, but this one glimmer of light has the potential to change that perception.

Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics

Battle of the speculative biotechs.

Arena Pharmaceuticals, Inc. Earnings: What to Expect Thursday

Will the obesity-drug maker avoid its biggest competitor's fate?

Why SINA, VIVUS, and Tenet Healthcare Tumbled Today

Even as the stock market gave up a small amount of ground today, these stocks got hammered hard. Find out why here.

See More OREX News...





Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website: http://www.orexigen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks